https://pubmed.ncbi.nlm.nih.gov/19841321/
The study did not meet its primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to...
phase ii trialsecond linepemetrexedplusbevacizumab
https://klinikaionkologia.hu/beyond-second-line-therapy-in-patients-with-metastatic-colorectal-cancer-a-systematic-review/
D. Arnold (1, 2), G. W. Prager (3), A. Quintela (1), A. Stein (4), S. Moreno Vera (5), N. Mounedji (5), J. Taieb (6) (1) Instituto CUF de Oncologia, Lisbon,...
second line therapymetastatic colorectal cancerbeyondpatients